Clinical Trial Update: Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update describes evaluating adjunctive allogeneic mesenchymal stem cells for treatment-resistant bipolar depression. The study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• Allogeneic mesenchymal stem cells (mesenchymal stem cells)

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Treatment-resistant Bipolar Depression | Phase 1 | Status: RECRUITING